Amarin Corp Plc (AMRN)

[rosemountbomber]

Don't know North. It would have to be some profound noticeable effect for the researchers to delve into it, as the study protocol and goals don't encompass such:

"The proposed study is a proof-of-concept, randomized, placebo-controlled, double-blind, parallel-group clinical trial assessing the efficacy of 18 months of icosapent ethyl (IPE) therapy on magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), and cognitive biomarkers for AD in 150 cognitively-healthy Veterans ages 50-75 years. The overarching goal of this trial is to assess whether icosapent ethyl beneficially affects intermediate physiological measures associated with onset of AD in order to evaluate whether larger, multi-site, longer-duration Alzheimer's prevention trials are warranted to assess more definitive clinical outcomes. The proposed study aims to: 1) investigate the effects of 18 months of IPE vs. placebo on regional cerebral blood flow as measured by arterial spin-labeling MRI; 2) determine the impact of 18 months of IPE vs. placebo on CSF biomarkers of AD pathology; and 3) evaluate the effects of 18 months of IPE vs. placebo on cognitive performance."
https://www.clinicaltrials.gov/study/NCT02719327?cond=Alzheimer%20disease&intr=Icosapent%20Ethyl&rank=1&tab=history&a=16

NORTH, I take all that BACK.. I found this on an Univ. of Wisconsin Department of Radiology website:

"In addition, data collection from this trial will allow for exploration of the impact of previous TBI and/or PTSD on response to therapy. We hypothesize that in this population, IPE will beneficially affect mechanisms central to AD pathology by: 1) increasing rCBF within the sROI; 2) reducing CSF A-beta-42; and that these neurobiological changes will be associated with 3) an increased ADCS-PACC cognitive composite score. While recognizing that the proposed trial is not addressing all potential effects of IPE, such as changes in measures of inflammation or oxidative stress, we will store neuroimages and blood and CSF samples for future analyses of other potential mechanisms."
https://radiology.wisc.edu/research-projects/brave-epa-brain-amyloid-and-vascular-effects-of-eicosapentaenoic-acid-epa-in-adults-at-risk-for-alzheimers-disease/